8-K: Abbott Laboratories Reports Strong First-Quarter 2025 Results, Reaffirms Full-Year Guidance

Abbott Laboratories announced positive first-quarter 2025 results, with sales growth and adjusted EPS exceeding expectations, and reaffirmed its full-year 2025 financial guidance.

Summary

• Abbott Laboratories reported a 4.0 percent increase in first-quarter sales on a reported basis, reaching $10.358 billion.
• Organic sales grew by 6.9 percent, or 8.3 percent when excluding COVID-19 testing-related sales.
• GAAP diluted EPS was $0.76, while adjusted diluted EPS reached $1.09, showing double-digit growth compared to the previous year.
• The company reaffirmed its full-year 2025 financial guidance, projecting organic sales growth between 7.5% and 8.5%.
• Abbott's adjusted operating margin is expected to be between 23.5% and 24.0% of sales for the full year.
• The company anticipates full-year adjusted diluted earnings per share to be in the range of $5.05 to $5.25.
• A quarterly dividend of $0.59 per share was declared, payable on May 15, 2025.
• Medical Devices sales increased 9.9 percent on a reported basis and 12.6 percent on an organic basis.
• Diagnostics sales decreased 7.2 percent on a reported basis, decreased 4.9 percent on an organic basis, or increased 0.5 percent when excluding COVID-19 testing-related sales.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, reaffirmation of guidance, and strategic product advancements. The tone is optimistic, reflecting confidence in the company's performance and future prospects.

Positives

• Strong sales growth in the first quarter, driven by Medical Devices and Nutrition segments.
• Double-digit growth in adjusted diluted EPS.
• Reaffirmation of full-year 2025 financial guidance.
• Successful product launches and clinical trial initiations, including the Volt PFA System and Coronary IVL System.
• Continued dividend increases, marking 53 consecutive years.
• Significant growth in Diabetes Care, particularly in continuous glucose monitors.
• Adjusted gross margin increased 140 basis points to 57.1 percent.

Negatives

• Diagnostics sales decreased 7.2 percent on a reported basis, impacted by declining COVID-19 testing-related sales and volume-based procurement programs in China.
• COVID-19 testing-related sales decreased from $204 million in Q1 2024 to $84 million in Q1 2025.
• Organic sales in Diagnostics decreased 4.9 percent.

Risks

• The company faces risks and uncertainties that may cause actual results to differ materially from forward-looking statements.
• Economic, competitive, governmental, and technological factors could affect Abbott's operations.
• Decline in COVID-19 testing-related sales could continue to impact Diagnostics sales.
• Volume-based procurement programs in China may continue to affect Core Laboratory Diagnostics sales.

Future Outlook

Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5% and adjusted diluted earnings per share of $5.05 to $5.25.

Management Comments

• 'Once again, Abbott's diversified business model delivered top-tier sales and EPS growth,' said Robert B. Ford, chairman and chief executive officer, Abbott.
• 'It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth.'

Industry Context

Abbott's performance reflects a broader trend in the healthcare industry, with a focus on diversified portfolios and innovation in medical devices and diagnostics. The company's growth in Medical Devices, particularly in Diabetes Care, aligns with the increasing demand for advanced healthcare technologies.

Comparison to Industry Standards

• Abbott's organic sales growth of 6.9% is competitive compared to peers like Medtronic and Johnson & Johnson, which also have diversified healthcare portfolios.
• The 21.0% adjusted operating margin is strong, placing Abbott among the top performers in the medical device industry.
• The growth in Diabetes Care, driven by FreeStyle Libre, positions Abbott as a leader in the continuous glucose monitoring market, competing with companies like Dexcom and Senseonics.
• The CE Mark approval for the Volt PFA System allows Abbott to compete with companies like Boston Scientific and Medtronic in the atrial fibrillation treatment market.

Stakeholder Impact

• Shareholders will benefit from continued dividend payouts and potential stock appreciation due to strong financial performance.
• Employees may experience job security and growth opportunities due to company expansion and investments.
• Customers will have access to innovative healthcare technologies and products.
• Suppliers may see increased demand for their products and services.
• Creditors can be assured of the company's financial stability and ability to meet its obligations.

Next Steps

• Expand the use of Volt PFA System in EU markets throughout the second half of the year.
• Continue the U.S. pivotal trial, TECTONIC, to evaluate the Coronary Intravascular Lithotripsy (IVL) System.
• Bring two new manufacturing and R&D investments in Illinois and Texas live by the end of 2025.

Key Dates

Keywords

Abbott, Financial Results, First Quarter 2025, Sales Growth, EPS, Guidance, Medical Devices, Diagnostics, Nutrition, Dividends, Organic Sales, COVID-19 Testing